详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Endothelial-to-mesenchymal transition in the tumor microenvironment: Roles of transforming growth factor-β and matrix metalloproteins

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China [2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China [3]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China [4]Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China [5]Department of Gastroenterology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China [6]Department of Pharmacy, Meishan TianFu New Area People’s Hospital, Meishan, Sichuan, China

出处：

DOI：

ISSN：

关键词： EndMT TME TGF-β MMPs Combination therapy

摘要：

Cancer is a leading cause of global morbidity and mortality. Tumor cells grow in a complex microenvironment, comprising immune cells, stromal cells, and vascular cells, collaborating to support tumor growth and facilitate metastasis. Transforming growth factor-beta (TGF-β) is a multipotent factor that can not only affect fibrosis promotion but also assume distinct roles in the early and late stages of the tumor. Matrix metalloproteinases (MMPs) primarily function to degrade the extracellular matrix, a pivotal cellular player in tumor progression. Moreover, endothelial-to-mesenchymal transition (EndMT), similar to epithelial-to-mesenchymal transition, is associated with cancer progression by promoting angiogenesis, disrupting the endothelial barrier, and leading to cancer-associated fibroblasts. Recent studies have underscored the pivotal roles of TGF-β and MMPs in EndMT. This review delves into the contributions of TGF-β and MMPs, as well as their regulatory mechanisms, within the tumor microenvironment. This collective understanding offers fresh insights into the potential for combined targeted therapies in the fight against cancer.© 2024 Published by Elsevier Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China [2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China [3]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China [6]Department of Pharmacy, Meishan TianFu New Area People’s Hospital, Meishan, Sichuan, China

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China [2]Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China [3]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Metabolic Reprogramming of Mammary Epithelial Cells during TGF-β-Induced Epithelial-to-Mesenchymal Transition. [2]Retinoic acid and TGF-β orchestrate organ-specific programs of tissue residency [3]化纤汤防治放射性肺纤维化的实验研究 [4]Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling. [5]MAGI2 ameliorates podocyte apoptosis of diabetic kidney disease through communication with TGF-β-Smad3/nephrin pathway [6]MAGI2 ameliorates podocyte apoptosis of diabetic kidney disease through communication with TGF-β-Smad3/Nephrin pathway [7]Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling. [8]Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function. [9]TGF-β RⅡ与HER-2阴性乳腺癌患者预后的关系研究 [10]TGF-β在足细胞生理功能及病理损伤中的作用